HMGB1 and neoplasm: The interactions between HMGB1 and TLR-2, TLR-4, and TLR-9 could also participate in cross-presentation of anti-tumor T lymphocytes in vivo, which lead to the activation of DCs and trigger antitumor immune responses (58, 59).